Inmune Bio, Inc. (INMB) · Oct 21, 2026 · Other events

INmune Bio agreement expands Ebstrocel access as UK filing shifts

UK filing accelerated — Potential UK approval about six weeks sooner

INmune Bio signs an Ebstrocel commercialization agreement while replacing its UK rolling filing with a full February 2027 application.

INmune Bio is a late-stage biotechnology company trying to move Ebstrocel from manufacturing and regulatory preparation toward its first commercial market, while XPro remains a separate late-stage pipeline program. Recent manufacturing progress and MHRA alignment had already put Ebstrocel near the registration stage.

The regulatory path has improved, but the submission date itself moves later. INmune is replacing the rolling UK submission planned for late 2026 with one complete MAA targeted for February 2027. 〔0〕 The company says the consolidated approach could bring potential UK approval forward by roughly six weeks, but that remains conditional on MHRA validation, review and information requests. 〔1〕

The filing advances commercial readiness without creating revenue yet. The Uniphar agreement gives INmune a framework for named-patient supply in selected European and MENA markets and could provide storage, distribution, treatment-site onboarding and related services. However, implementation depends on country-specific statements of work, applicable law, approvals, pricing and reimbursement; Ebstrocel remains investigational, so this is infrastructure rather than a commercial launch or booked sales.

The U.S. plan becomes the next major regulatory branch. INmune is preparing an FDA Type B meeting request and now targets a BLA in the second quarter of 2027, subject to FDA feedback. 〔2〕 That creates a clearer 2027 regulatory sequence, but no agency has accepted the proposed approval timing.

Bottom line: This is executional progress toward commercialization, not an approval or revenue event. The UK route looks more efficient and international access is being built, but the agreement has no disclosed economics and the key outcomes remain regulatory decisions.

What to watch next

Full UK MAA submission, early February 2027

Original filing on SEC EDGAR

More Inmune Bio, Inc. news

INmune Bio agreement expands Ebstrocel access as UK filing shifts | INMB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.